Investor Presentaiton

Transaction price is up to USD 1.3 billion (around DKK 8.9 billion) with closing expected during Q4 2022/23 Structure and valuation • • Financing Capital allocation policy . • Coloplast acquires Kerecis for an enterprise value of up to USD 1.3 billion (around DKK 8.9 billion) Total price for 100% of the share capital is USD 1.2 billion (around DKK 8.2 billion), on a cash and debt free basis Additional earnout potential of maximum USD 100 million (around DKK 680 million) dependent on financial performance in FY 2023/24 The transaction is expected to be financed through an equity issue*, with anticipated completion in Q4 2022/23 Coloplast's largest existing shareholder, Niels Peter Louis-Hansen, and family are supportive of the acquisition and expect to participate in the equity capital raise An equity bridge facility matching the total price for 100% of the share capital has been provided by Danske Bank and Nordea No changes to Coloplast's capital allocation and dividend policy to return excess liquidity to shareholders through dividends and share buy-backs Unchanged target pay-out ratio of 60-80% of net profit Unchanged leverage expectations - target range of 1-2x NIBD/EBITDA by the end of the Strive25 period 51 Transaction costs Transaction related costs (advisory fees) are expected to be around DKK 50 million, included under special items in FY 2022/23 Deal certainty and timing Subject to customary regulatory approvals and an acceptance threshold of at least 90%. As of August 17, around 99% of Kerecis' shareholders have committed to sell their shares to Coloplast Closing of the transaction is anticipated in Q4 2022/23 *Equity issue via an accelerated bookbuilding without pre-emption rights for existing shareholders Coloplast

View entire presentation